PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Conditions:   Small Cell Lung Cancer;   Gastric Adenocarcinoma;   Esophageal Adenocarcinoma;   Castration Resistant Prostate Adenocarcinoma;   Soft Tissue Sarcoma;   Ovarian Adenocarcinoma;   Advanced Well-differentiated Neuroendocrine Tumors;   Diffuse Large B Cell Lymphoma
Interventions:   Biological: PDR001;   Biological: LAG525
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting

http://ift.tt/2Bccuj0